Enantioselective copper-catalyzed synthesis of trifluoromethyl-cyclopropylboronates

Julia Altarejos, David Sucunza, Juan J. Vaquero, Javier Carreras*

Universidad de Alcalá, Departamento de Química Orgánica y Química Inorgánica, Instituto de Investigación Química Andrés Manuel del Río (IQAR), Alcalá de Henares 28805, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid 28034, Spain; E-mail: javier.carreras@uah.es

up to 95:5 dr, 97:3 er

ABSTRACT: A copper-catalyzed enantioselective cyclopropanation involving trifluorodiazoethane in the presence of alkenyl boronates has been developed. This transformation enables the preparation of 2-substituted-3-(trifluoromethyl)cyclopropylboronates with high levels of stereocontrol. The products are valuable synthetic intermedi-ates by transformation of the boronate group. This methodology can be applied to the synthesis of novel trifluoromethyl-ated analogues of trans-2-arylcyclopropylamines, which are prevalent motifs in biologically active compounds.

Cyclopropanes are widespread carbocycles in bioactive natural and synthetic compounds.[1] It is currently a standard fragment in drug discovery, which allows to modulate properties such as lipophilicity, metabolic stability, pK_a or binding, among others.[2] Nowadays, it is present in numerous drugs, for example *Ticagrelor*,[3] active against cardiovascular diseases, or *Tezacaftor*,[4] to treat cystic fibrosis.

Numerous methods have been described for the synthesis of substituted cyclopropanes.[5] Among all the different possibilities, the preparation of cyclopropanes with fluorinated groups, in particular trifluoromethyl, is of special interest.[6] This functional group is present in a vast number of therapeutic compounds.[7] However, the enantioselective procedures for the preparation of trifluoromethylcyclopropanes are scarce in the literature.[8] All the existing protocols, which are summarized in Scheme 1a, led to cyclopropanes with an unsubstituted carbon on the three-membered ring. For this reason, there is still a need to develop efficient enantioselective methodologies to prepare all-carbon-substituted trifluoromethylcyclopropanes.

On the other hand, the synthesis of versatile cyclopropanes, such as cyclopropylboronates, has also attracted the interest of the synthetic community.[9] A boronate group can be easily transformed into a wide range of different functional groups.[10] This allows the generation of compound libraries from a common structure. In this area, several strategies have been recently developed to prepare optically active cyclopropylboronates, including cyclopropanation of alkenyl boronates with diazo compounds,[11] borylative cyclization of allylic carbonates, phosphonates,[12] or epoxides,[13] hydroboration of cyclopropenes,[14] zinco-cyclopropanation of allylic alcohols[15] and C-H borylation.[16]

In this context, we focused our attention on the enantioselective preparation of cyclopropanes that include simultaneously a trifluoromethyl group and a pinacol boronate as substituents. These versatile compounds would give access to a wide range of trifluoromethyl-cyclopropane derivatives. In the literature, there are only three examples of this type of compounds, all of them obtained as racemates from monosubstituted vinyl boron derivatives (Scheme 1b).[17]

Herein, we report the enantioselective cyclopropanation of *trans*-alkenyl boronates with trifluorodiazoethane catalyzed by a copper(I)-bisoxazoline complex to obtain versatile 2-substituted-3-(trifluoromethyl)cyclopropylboronates. It is worth mentioning that the reactivity between alkenyl boroxines and trifluorodiazoethane has been recently reported to prepare α-trifluoromethyl allylboronic acids,[18] by formation of highly electrophilic BINOL boronate derivatives in a metal-free procedure.

Scheme 1. Previous synthesis of trifluoromethylcyclopropanes and trifluoromethyl-cyclopropylboronates.

a) Enantioselective synthesis of trifluoromethylcyclopropanes

b) Synthesis of 2-(trifluoromethyl)cyclopropylboronates/borate

The cyclopropanation was initially studied with (*E*)-styryl pinacolboronate (**1a**) as model substrate. We commenced using Cu(I)-*t*BuBOX (5 mol%) as catalyst formed *in situ* in DCE. Initial experiments showed that alkenyl boronate was not fully consumed with 2 equiv of diazo added over the course of 2 h (Table 1, entry 1). This point was crucial from a practical point of view, as cyclopropane **2a** was not easily separable from the starting material by column chromatography. Further increase of the amount of the diazo compound (4 equiv) combined with a longer reaction time (6 h) raised the conversion to 90% (entries 2-4). The relative configuration of cyclopropane **2a** was determined by ^{1}H NMR experiments (see Supporting Information).

Gratifyingly, good results of diastereo- and enantiocontrol were obtained under these catalytic conditions (92:8 dr, 95:5 er). We examined different organic solvents such as THF or toluene (see SI). Toluene significantly reduced reactivity and diastereoselectivity, and THF led to no conversion of the olefin. Subsequently we investigated different commercially available BOX ligands. Whereas the *i*PrBOX (**L2**) ligand decreased the conversion and stereocontrol of the reaction, PhBOX (**L3**) slightly improved the diastereoselectivity (entries 5-6). At this stage, concentration of trifluorodiazoethane was increased from *ca.* 0.5 to 1 M, conducting to complete conversion (entry 7). Furthermore, the amount of diazo compound could be reduced to 2 equivalents (entry 8).

Under the optimized conditions, using 5 mol% of [Cu(NCMe)$_4$]PF$_6$ and *t*BuBOX as the catalyst and 2 equiv of trifluorodiazoethane added during 6 hours, 69% of cyclopropylboronate **2a** was isolated, with high level of stereocontrol (94:6 dr, 95:5 er).

Table 1. Optimization of the Reaction Conditions.[a]

entry	ligand	diazo (equiv)	t (h)	conv (%)	dr	er
1	L1	2	2	72	92:8	-
2	L1	2	6	58	92:8	-
3	L1	4	2	89	92:8	-
4	L1	4	6	90	92:8	95:5
5	L2	4	6	72	79:21	88:12
6	L3	4	6	87	94:6	95:5
7	L3	4[b]	6	100	94:6	95:5
8	L3	2[b]	6	100 (69)[c]	94:6	95:5

[a]Reaction conditions: **1** (0.4 mmol), [Cu(NCMe)4]PF6 (0.02 mmol, 5 mol%), **L** (0.02 mmol, 5 mol%), DCE (1 mL), inert atmosphere, trifluorodiazoethane (0.5 M DCE, 2-4 equiv) 6 h slow addition. Conversion measured by 1H NMR. Diastereomeric ratio (dr) determined by 19F NMR analysis of the crude reaction mixture. Enantiomeric ratio (er) determined by HPLC analysis of the isolated product. [b]Trifluorodiazoethane (1.06 M DCE). [c]Isolated yield.

With the optimized conditions in hand, the scope of the cyclopropanation was examined (Scheme 2). The procedure was successful with a variety of (*E*)-alkenyl boranates, considering electron-withdrawing and electron-donating groups (alkyl, halogens, trifluoromethyl, ether and ester substituents) at different positions in the aromatic substituent of the olefin. Moderate to good yields were obtained for the whole series (40-77%) and high stereoselectivity was also achieved, in terms of diastereoselectivity (up to 95:5) and enantioselectivity (up to 97:3). Notably, both parameters increase as the electron density of the aromatic ring decreases. A similar result was obtained with an electron-rich heterocycle such as thiophene (**2l**), with moderate enantioselectivity (90:10 er). Furthermore, an aliphatic-substituted cyclopropane (**2m**) was also accessible with moderate yield and levels of enantioinduction. In several substrates, an increase of the equivalents of trifluorodiazoethane was necessary to achieve complete conversion, whereas the reaction was suppressed in the presence of functional groups such as nitrile or nitro. The absolute configuration of the stereogenic centers of the cyclopropane were determined by single crystal X-ray diffraction analysis of *p*-bromo and *p*-methoxy derivatives **2i** and **2l** (Scheme 2).[19]

Scheme 2. Substrate scope of copper-catalyzed cyclopropanation of alkenyl boronates.[a]

2a, R = H, 69%,[b] 94:6 dr, 95:5 er
2b, R = F, 45%, 94:6 dr, 97:3 er[c]
2c, R = CH₃, 55%, 91:9 dr, 95:5 er

2d, R = CH₃, 72%, 94:6 dr, 95:5 er
2e, R = F, 68%, 96:4 dr, 96:4 er
2f, R = OAc, 50%, 93:7 dr, 96:4 er[d]

2g, R = CH₃, 77%, 92:8 dr, 93:7 er
2h, R = Cl, 40%, 95:5 dr, 97:3 er[d]
2i, R = Br, 52%, 95:5 dr, 96:4 er[d]
2j, R = CF₃, 61%, 95:5 dr, 96:4 er
2k, R = tBu, 59%, 92:8 dr, 89:11 er[d]
2l, R = OMe, 60%, 86:14 dr, 90:10 er
2m, R = CN, no reaction
2n, R = NO₂, no reaction
2o, R = CO₂Me, 51%, 94:6 dr, 95:5 er

X-ray structure of 2i[e]   X-ray structure of 2l[e]

2p, 62%, 90:10 dr, 96:4 er   2q, 50%, 93:7 dr, 90:10 er[d]   2r, 50%, 96:4 dr, 92:8 er[c]

[a]Reaction conditions: 1 (0.61 mmol), [Cu(NCMe)₄]PF₆ (0.03 mmol, 5 mol%), (S,S)-L3 (0.03 mmol, 5 mol%), DCE (1.5 mL), inert atmosphere trifluorodiazoethane in DCE (2 equiv), 6 h slow addition. Isolated yields. [b]76% at 1.25 mmol scale. [c]Trifluorodiazoethane (6 equiv). [d]Trifluorodiazoethane (4 equiv). [e]Thermal ellipsoids are drawn at the 50% probability level.

As mentioned above, cyclopropylboronates are versatile intermediates in organic synthesis by the transformation of the carbon-boron bond. To highlight the synthetic utility of the new compounds, we performed several transformations of the pinacol boronate group following reported methodologies (Scheme 3). Boronic acid **3** was smoothly obtained by treatment with methylboronic acid.[20] Standard conditions of Suzuki-Miyaura cross-coupling led to 3-trifluoromethyl-1,2-diarylsubstituted cyclopropane **4** in good yield. Furthermore, oxidation of the boronate group could be achieved under basic conditions to get alcohol **5**. Finally, amination of the cyclopropylboronate was accomplished by using BCl₃ and BnN₃ to get the benzylamine derivative in good yield (**6**).[21] The latter transformations gave access to substituted *trans*-2-trifluoromethylcyclopropan-1-amine and *trans*-2-trifluoromethylcyclopropanol, rarely described in the literature in an enantioselective manner.[22]

Scheme 3. Transformations of cyclopropylboronate ester.

[a]Reaction conditions: (a) MeB(OH)₂ (5 equiv), TFA (5%)/DCM, 8 h, 72%. (b) 4-iodoanisole (1.5 equiv), Pd₂(dba)₃·CHCl₃ (10 mol %), PPh₃ (1 equiv), Ag₂O (1.5 equiv), THF, 70 °C, 24 h, 45 %. (c) 3M NaOH 30% H₂O₂ THF, 30 min, 68%. (d) BCl₃ (5.0 equiv, CH₂Cl₂, 25 °C, 1.5 h), then BnN₃ (3.0 equiv, CH₂Cl₂, from 0 to 25 °C, 2 h), 51%.

Then, we focused our interest in amine derivative **6**, as a trifluoromethylated analogue of *trans*-2-arylcyclopropylamines. This scaffold is common to numerous biological active compounds[23] and is present in drugs such as *Tranylcypromine* (antidepressant), *Ticagrelor* (platelet aggregation inhibitor) or candidates under clinical trials for the treatment of cancer and neurodegenerative diseases.[23,24] Due to the implication of fluorine atoms in the properties of bioactive compounds, [25] we targeted the enantioselective synthesis of a CF_3 analogue of a lysine-specific demethylase 1 (LSD1) inhibitor (Scheme 4). The amination of cyclopropylboronate **2a** with 3-(azidomethyl)-2-methoxypyridine (**7**) allowed us to obtain the trifluoromethyl analogue **8** of LSD1 inhibitor in a good yield.

Scheme 4. Preparation of a trifluoromethyl analog of LSD1 inhibitor.

[a]Reaction conditions: (a) BCl_3 (5.0 equiv, CH_2Cl_2, 25 °C, 1.5 h), then **7** (3.0 equiv, CH_2Cl_2, from 0 to 25 °C, 4 h), 55%.

In summary, we have developed a catalytic approach for the preparation of enantiomerically enriched 2-substituted-3-(trifluoromethyl)cyclopropylboronates by cyclopropanation of (*E*)-alkenyl boronates with trifluorodiazoethane. This methodology is general for a variety of substrates, using commercially available copper catalyst and ligand. Valuable synthetic intermediates can be obtained by the functionalization of the C−B bond. This route provides straightforward access to enantioenriched 2-aryl-3-(trifluoromethyl)cyclopropylamines, a relevant scaffold in medicinal chemistry.

ASSOCIATED CONTENT

Supporting Information
The Supporting Information is available free of charge on the ACS Publications website.

Experimental procedures, characterization data, ^{1}H, ^{13}C, ^{11}B and ^{19}F NMR spectral data, HPLC, mass spectrometry data of new compounds and X-ray crystallographic data for **2i** and **2l** (PDF)

Accession Codes
CCDC 2079480 and 2079481 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Author

Javier Carreras - Universidad de Alcalá. Departamento de Química Orgánica y Química Inorgánica, Instituto de Investigación Química Andrés Manuel del Río (IQAR), Campus Científico-Tecnológico, Facultad de Farmacia. 28805 Alcalá de Henares, Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid 28034, Spain, ORCID: 0000-0002-1521-6758; E-mail: javier.carreras@uah.es

Authors

Julia Altarejos - Universidad de Alcalá. Departamento de Química Orgánica y Química Inorgánica, Instituto de Investigación Química Andrés Manuel del Río (IQAR), Campus Científico-Tecnológico, Facultad de Farmacia. 28805 Alcalá de Henares, Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid 28034, Spain, ORCID: 0000-0002-2871-8597

David Sucunza - Universidad de Alcalá. Departamento de Química Orgánica y Química Inorgánica, Instituto de Investigación Química Andrés Manuel del Río (IQAR), Campus Científico-Tecnológico, Facultad de Farmacia. 28805 Alcalá de Henares, Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid 28034, Spain, ORCID: 0000-0002-3307-4204

Juan J. Vaquero - Universidad de Alcalá. Departamento de Química Orgánica y Química Inorgánica, Instituto de Investigación Química Andrés Manuel del Río (IQAR), Campus Científico-Tecnológico, Facultad de Farmacia. 28805 Alcalá de Henares, Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid 28034, Spain, ORCID: 0000-0002-3820-9673

Notes
The authors declare no competing financial interest.

REFERENCES

(1) For selected reviews, see: (a) Ebner, C.; Carreira, E. M. Cyclo-propanation Strategies in Recent Total Syntheses. Chem. Rev. 2017, 117, 11651–11679. (b) Časar, Z. Synthetic Approaches to Contemporary Drugs That Contain the Cyclopropyl Moie-ty. Synthesis 2020, 52, 1315–1345.

(2) (a) Talele, T. T. The "Cyclopropyl Fragment" Is a Versatile Player That Frequently Appears in Preclinical/Clinical Drug Molecules. J. Med. Chem. 2016, 59, 8712–8756. (b) Bauer, M. R.; Fruscia, P. D.; Lucas, S. C. C.; Michaelides, I. N.; Nelson, J. E.; Storer, R. I.; Whitehurst, B. C. Put a Ring on It: Application of Small Aliphatic Rings in Medicinal Chemistry. RSC Med. Chem. 2021, 12, 448–471.

(3) Wijeyeratne, Y. D.; Joshi, R.; Heptinstall, S. Ticagrelor: A P2Y12 Antagonist for Use in Acute Coronary Syndromes. Expert Rev. Clin. Pharmacol. 2012, 5, 257–269.

(4) Hughes, D. L. Patent Review of Synthetic Routes and Crystal-line Forms of the CFTR-Modulator Drugs Ivacaftor, Lu-macaftor, Tezacaftor, and Elexacaftor. Org. Process Res. Dev. 2019, 23, 2302–2322.

(5) Pellissier, H., Lattanzi, A. and Dalpozzo, R. Asymmetric Cyclo-propanation. In Asymmetric Synthesis of Three-Membered Rings; John Wiley & Sons, Ltd, 2017; pp 1–204.

(6) For a selected reviews, see: (a) Decaens, J.; Couve-Bonnaire, S.; Charette, A. B.; Poisson, T.; Jubault, P. Synthesis of Fluoro-, Monofluoromethyl-, Difluoromethyl-, and Trifluoromethyl-Substituted Three-Membered Rings. Chem. Eur. J. 2021, 27, 2935–2962. For recent examples: (b) Cyr, P.; Flynn-Robitaille, J.; Boissarie, P.; Marinier, A. Mild and Diazo-Free Synthesis of Trifluoromethyl-Cyclopropanes Using Sul-

fonium Ylides. Org. Lett. 2019, 21, 2265–2268. (c) Chen, G.-S.; Yan, X.-X.; Chen, S.-J.; Mao, X.-Y.; Li, Z.-D.; Liu, Y.-L. Diastereose-lective Synthesis of 1,3-Diyne-Tethered Trifluoromethylcy-clopropanes through a Sulfur Ylide Mediated Cyclopropana-tion/DBU-Mediated Epimerization Sequence. J. Org. Chem. 2020, 85, 6252–6260. (d) Chernykh, A. V.; Olifir, O. S.; Kuchkovska, Y. O.; Volochnyuk, D. M.; Yarmolchuk, V. S.; Grygorenko, O. O. Fluoroalkyl-Substituted Cyclopropane De-rivatives: Synthesis and Physicochemical Properties. J. Org. Chem. 2020, 85, 12692–12702.

(7) Meanwell, N. A. Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. J. Med. Chem. 2018, 61, 5822–5880.

(8) (a) Maux, P. L.; Juillard, S.; Simonneaux, G. Asymmetric Syn-thesis of Trifluoromethylphenyl Cyclopropanes Catalyzed by Chiral Metalloporphyrins. Synthesis 2006, 1701–1704. (b) Denton, J. R.; Sukumaran, D.; Davies, H. M. L. Enantioselective Synthesis of Trifluoromethyl-Substituted Cyclopropanes. Org. Lett. 2007, 9, 2625–2628. (c) Morandi, B.; Mariampillai, B.; Carreira, E. M. Enantioselective Cobalt-Catalyzed Prepara-tion of Trifluoromethyl-Substituted Cyclopropanes. Angew. Chem. Int. Ed. 2011, 50, 1101–1104. (d) Tinoco, A.; Steck, V.; Tyagi, V.; Fasan, R. Highly Diastereo- and Enantioselective Synthesis of Trifluoromethyl-Substituted Cyclopropanes via Myoglobin-Catalyzed Transfer of Trifluoromethylcarbene. J. Am. Chem. Soc. 2017, 139, 5293–5296. (e) Kotozaki, M.; Chanthamath, S.; Fujii, T.; Shibatomi, K.; Iwasa, S. Highly Enan-tioselective Synthesis of Trifluoromethyl Cyclopropanes by Using Ru(II)–Pheox Catalysts. Chem. Commun. 2018, 54, 5110–5113. (f) Huang, W.-S.; Schlinquer, C.; Poisson, T.; Pannecoucke, X.; Charette, A. B.; Jubault, P. General Catalytic Enantioselective Access to Monohalomethyl and Trifluoro-methyl Cyclopropanes. Chem. Eur. J. 2018, 24, 10339–10343. (g) Carminati, D. M.; Decaens, J.; Couve-Bonnaire, S.; Jubault, P.; Fasan, R. Biocatalytic Strategy for the Highly Stereoselective Synthesis of CHF2-Containing Trisubstituted Cyclopropanes. Angew. Chem. Int. Ed. 2021, 60, 7072–7076.

(9) Martín-Heras, V.; Parra, A.; Tortosa, M. Cyclopropyl- and Cy-clobutylboronates and -Silanes: A Stereo¬selective Approach. Synthesis 2018, 50, 470–484.

(10) Sandford, C.; Aggarwal, V. K. Stereospecific Functionalizations and Transformations of Secondary and Tertiary Boronic Es-ters. Chem. Commun. 2017, 53, 5481–5494.

(11) (a) Carreras, J.; Caballero, A.; Pérez, P. J. Enantio- and Dia-stereoselective Cyclopropanation of 1-Alkenylboronates: Synthesis of 1-Boryl-2,3-Disubstituted Cyclopropanes. An-gew. Chem. Int. Ed. 2018, 57, 2334–2338 and references cited therein. (b) Sun, X.; Gu, P.; Qin, J.; Su, Y. Rhodium-Catalysed Di-astereo- and Enantio-Selective Cyclopropanation of α-Boryl Styrenes. Chem. Commun. 2020, 56, 12379–12382.

(12) (a) Ito, H.; Kosaka, Y.; Nonoyama, K.; Sasaki, Y.; Sawamura, M. Synthesis of Optically Active Boron–Silicon Bifunctional Cy-clopropane Derivatives through Enantioselective Copper(I)-Catalyzed Reaction of Allylic Carbonates with a Diboron De-rivative. Angew. Chem. Int. Ed. 2008, 47, 7424–7427. (b) Zhong, C.; Kunii, S.; Kosaka, Y.; Sawamura, M.; Ito, H. Enanti-oselective Synthesis of Trans-Aryl- and -Heteroaryl-Substituted Cyclopropylboronates by Copper(I)-Catalyzed Reactions of Allylic Phosphates with a Diboron Derivative. J. Am. Chem. Soc. 2010, 132, 11440–11442.

(13) Amenós, L.; Trulli, L.; Nóvoa, L.; Parra, A.; Tortosa, M. Stereo-specific Synthesis of α-Hydroxy-Cyclopropylboronates from Allylic Epoxides. Angew. Chem. Int. Ed. 2019, 58, 3188–3192.

(14) (a) Rubina, M.; Rubin, M.; Gevorgyan, V. Catalytic Enantiose-lective Hydroboration of Cyclopropenes. J. Am. Chem. Soc. 2003, 125, 7198–7199. (b) Tian, B.; Liu, Q.; Tong, X.; Tian, P.; Lin, G.-Q. Copper(I)-Catalyzed Enantioselective Hydrobora-tion of Cyclopropenes: Facile Synthesis of Optically Active Cyclopropylboronates. Org. Chem. Front. 2014, 1, 1116–1122. (c) Parra, A.; Amenós, L.; Guisán-Ceinos, M.; López, A.; García Ruano, J. L.; Tortosa, M. Copper-Catalyzed Diastereo- and Enantioselective Desymmetrization of Cyclopropenes: Synthesis of Cyclopropylboronates. J. Am. Chem. Soc. 2014, 136, 15833–15836 and references cited therein.

(15) Zimmer, L. E.; Charette, A. B. Enantioselective Synthesis of 1,2,3-Trisubstituted Cyclopropanes Using gem-Dizinc Rea-gents. J. Am. Chem. Soc. 2009, 131, 15624–15626.

(16) Shi, Y.; Gao, Q.; Xu, S. Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)–H Borylation of Cyclopropanes. J. Am. Chem. Soc. 2019, 141, 10599–10604.

(17) (a) Duncton, M. A. J.; Ayala, L.; Kaub, C.; Janagani, S.; Edwards, W. T.; Orike, N.; Ramamoorthy, K.; Kincaid, J.; Kelly, M. G. Dibutyl 2-(Trifluoromethyl)Cyclopropylboronate as a Useful (Trifluoromethyl)Cyclopropyl Donor: Application to Antag-onists of TRPV1. Tetrahedron Lett. 2010, 51, 1009–1011. (b) Duncton, M. A. J.; Singh, R. Synthesis of Trans-2-(Trifluoromethyl)Cyclopropanes via Suzuki Reactions with an N-Methyliminodiacetic Acid Boronate. Org. Lett. 2013, 15, 4284–4287. (c)

Hryschuk, O. V.; Yurov, Y.; Tymtsunik, A. V.; Kovtunenko, V. O.; Komarov, I. V.; Grygorenko, O. O. Multi-gram Synthesis and C−C/C−N Couplings of Functionalized 1,2-Disubstituted Cyclopropyltrifluoroborates. Adv. Synth. Catal. 2019, 361, 5428–5439. (d) A chiral cyclopropyl PIDA boronate has been described in a patent: Duncton, M.; Burke, M. D. Cyclopropyl PIDA Boronate. US20130331585 A1, 2013.

(18) Jonker, S. J. T.; Jayarajan, R.; Kireilis, T.; Deliaval, M.; Eriksson, L.; Szabó, K. J. Organocatalytic Synthesis of α-Trifluoromethyl Allylboronic Acids by Enantioselective 1,2-Borotropic Mi-gration. J. Am. Chem. Soc. 2020, 142, 21254–21259.

(19) CCDC 2079481 (2h) and CCDC 2079480 (2k) contain the supplementary crystallographic data. These data can be ob-tained free of charge from The Cambridge Crystallographic Data Centre.

(20) Hinkes, S. P. A.; Klein, C. D. P. Virtues of Volatility: A Facile Transesterification Approach to Boronic Acids. Org. Lett. 2019, 21, 3048–3052.

(21) Hupe, E.; Marek, I.; Knochel, P. Diastereoselective Reduction of Alkenylboronic Esters as a New Method for Controlling the Stereochemistry of up to Three Adjacent Centers in Cyclic and Acyclic Molecules. Org. Lett. 2002, 4, 2861–2863.

(22) See reference 8e. For some racemic examples: (a) Mykhailiuk, P. K.; Afonin, S.; Ulrich, A. S.; Komarov, I. V. A Convenient Route to Trifluoromethyl-Substituted Cyclopropane Deriva-tives. Synthesis 2008, 1757–1760. (b) Yarmolchuk, V.; Bezdudny, A.; Tolmacheva, N.; Lukin, O.; Boyko, A.; Chekoty-lo, A.; Tolmachev, A.; Mykhailiuk, P. An Efficient and Safe Method for the Multigram Synthesis of Trans-2-(Trifluoromethyl)Cyclopropylamine Synthesis 2012, 44, 1152–1154 and references cited therein.

(23) (a) Miyamura, S.; Itami, K.; Yamaguchi, J. Syntheses of Biologi-cally Active 2-Arylcyclopropylamines. Synthesis 2017, 49, 1131–1149. For recent synthetic examples: (b) Miyamura, S.; Araki, M.; Suzuki, T.; Yamaguchi, J.; Itami, K. Stereodivergent Synthesis of Arylcyclopropylamines by Sequential C-H Borylation and Suzuki–Miyaura Coupling. Angew. Chem. Int. Ed. 2015, 54, 846–851. (c) Li, Z.; Zhang, M.; Zhang, Y.; Liu, S.; Zhao, J.; Zhang, Q. Multicomponent Cyclopropane Synthesis Enabled by Cu-Catalyzed Cyclopropene Carbometalation with Organoboron Reagent: Enantioselective Modular Access to Polysubstituted 2-Arylcyclopropylamines. Org. Lett. 2019, 21, 5432–5437.

(24) (a) Hitchin, J. R.; Blagg, J.; Burke, R.; Burns, S.; Cockerill, M. J.; Fairweather, E. E.; Hutton, C.; Jordan, A. M.; McAndrew, C.; Mirza, A.; Mould, D.; Thomson, G. J.; Waddell, I.; Ogilvie, D. J. Development and Evaluation of Selective, Reversible LSD1 Inhibitors Derived from Fragments. Med. Chem. Commun. 2013, 4, 1513–1522. (b) Schulz-Fincke, J.; Hau, M.; Barth, J.; Robaa, D.; Willmann, D.; Kürner, A.; Haas, J.; Greve, G.; Haydn, T.; Fulda, S.; Lübbert, M.; Lüdeke, S.; Berg, T.; Sippl, W.; Schüle, R.; Jung, M. Structure-Activity Studies on N-Substituted Tranylcypromine Derivatives Lead to Selective Inhibitors of Lysine Specific Demethylase 1 (LSD1) and Potent Inducers of Leukemic Cell Differentiation. Eur. J. Med. Chem. 2018, 144, 52–67. (c) Herrlinger, E.-M.; Hau, M.; Redhaber, D. M.; Greve, G.; Willmann, D.; Steimle, S.; Müller, M.; Lübbert, M.; Miething, C. C.; Schüle, R.; Jung, M. Nitroreductase-Mediated Release of Inhibitors of Lysine-Specific Demethylase 1 (LSD1) from Prodrugs in Transfected Acute Myeloid Leukaemia Cells. ChemBioChem 2020, 21, 2329–2347.

(25) Monofluorinated tranylcypromine analogues have been pre-viously studied: Borrello, M. T.; Schinor, B.; Bartels, K.; Ben-elkebir, H.; Pereira, S.; Al-Jamal, W. T.; Douglas, L.; Duriez, P. J.; Packham, G.; Haufe, G.; Ganesan, A. Fluorinated Tranylcy-promine Analogues as Inhibitors of Lysine-Specific Deme-thylase 1 (LSD1, KDM1A). Bioorg. Med. Chem. Lett. 2017, 27, 2099–2101.